Doets, AY, Lingsma, HF, Walgaard, C, et al.; IGOS Consortium. Predicting outcome in Guillain-Barré syndrome: international validation of the modified Erasmus GBS Outcome Score. Neurology 2022;98(5):e518–e532. doi: 10.1212/WNL.0000000000013139. Epub 2021 Dec 22. PMID: 34937789; PMCID: PMC8826467.CrossRefGoogle ScholarPubMed

Doets, AY, Walgaard, C, Lingsma, HF, et al.; IGOS Consortium. International validation of the Erasmus Guillain-Barré Syndrome Respiratory Insufficiency Score. Ann Neurol 2022;91(4):521–531. doi: 10.1002/ana.26312. Epub 2022 Feb 21. PMID: 35106830; PMCID: PMC9306880.CrossRefGoogle ScholarPubMed

van Doorn, PA, Van den Bergh PYK, Hadden RDM et al. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome. Eur J Neurol. 2023 Dec;30(12):3646–3674. doi: 10.1111/ene.16073. Epub 2023 Oct 10. PMID: 37814552; J Peripher Nerv Syst. 2023 Dec;28(4):535–563. doi: 10.1111/jns.12594. Epub ahead of print 2023 Oct 10 PMID: 37814552Google Scholar

Leonhard, SE, Mandarakas, MR, Gondim, FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol 2019;15(11):671–683. doi: 10.1038/s41582-019-0250-9. Epub 2019 Sep 20. PMID: 31541214; PMCID: PMC6821638.Google ScholarPubMed

Walgaard, C, Jacobs, BC, Lingsma, HF, et al.; Dutch GBS Study Group. Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurol 2021;20(4):275–283. doi: 10.1016/S1474-4422(20)30494-4. Epub 2021 Mar 17. PMID: 33743237.CrossRefGoogle ScholarPubMed

Walgaard, C, Lingsma, HF, Ruts, L, et al. Early recognition of poor prognosis in Guillain-Barré syndrome. Neurology 2011;76(11):968–975. doi: 10.1212/WNL.0b013e3182104407. PMID: 21403108; PMCID: PMC3059137.CrossRefGoogle ScholarPubMed

Willison, HJ, Jacobs, BC, van Doorn, PA. Guillain-Barré syndrome. Lancet. 2016 Aug 13;388(10045):717–727. doi: 10.1016/S0140-6736(16)00339-1. Epub 2016 Mar 2. PMID: 26948435.CrossRefGoogle ScholarPubMed

Adrichem, ME, Lucke, IM, Vrancken, AFJE, et al. Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Brain 2022;145(5):1641-1652. doi: 10.1093/brain/awac054. PMID: 35139161; PMCID: PMC9166547.CrossRefGoogle ScholarPubMed

Van den Bergh, PYK, van Doorn, PA, Hadden, RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force-Second revision. J Peripher Nerv Syst. 2021 Sep;26(3):242–268. doi: 10.1111/jns.12455. Epub 2021 Jul 30. Erratum in: J Peripher Nerv Syst 2022;27(1):94. Erratum in: Eur J Neurol. 2022 Apr;29(4):1288. PMID: 34085743.Bottom of FormCrossRefGoogle ScholarPubMed

Oaklander, AL, Lunn, MP, Hughes, RA, et al. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst Rev 2017;1(1):CD010369. doi: 10.1002/14651858.CD010369.pub2. PMID: 28084646; PMCID: PMC5468847.Google ScholarPubMed

Carroll, AS, Lunn, MPT. Paraproteinaemic neuropathy: MGUS and beyond. Pract Neurol 2021;21(6):492–503. doi: 10.1136/practneurol-2020-002837. Epub 2021 Jul 19. PMID: 34282034.CrossRefGoogle ScholarPubMed

Chaganti, S, Hannaford, A, Vucic, S. Rituximab in chronic immune mediated neuropathies: a systematic review. Neuromuscul Disord 2022;32(8):621–627. doi: 10.1016/j.nmd.2022.05.013. Epub 2022 May 24. PMID: 35672205.CrossRefGoogle ScholarPubMed

Lunn, MP, Nobile-Orazio, E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 2016;10(10):CD002827. doi: 10.1002/14651858.CD002827.pub4. PMID: 27701752; PMCID: PMC6457998.Google ScholarPubMed

Parisi, M, Dogliotti, I, Clerico, M, et al. Efficacy of rituximab in anti-myelin-associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow-up. Eur J Neurol 2022;29(12):3611–3622. doi: 10.1111/ene.15553. Epub 2022 Sep 25. PMID: 36083713; PMCID: PMC9825860.CrossRefGoogle ScholarPubMed

Sommer, C, Carroll, AS, Koike, H, et al. Nerve biopsy in acquired neuropathies. J Peripher Nerv Syst 2021;26 Suppl 2:S21–S41. doi: 10.1111/jns.12464. Epub 2021 Sep 14. PMID: 34523188.CrossRefGoogle ScholarPubMed

Taams, NE, Drenthen, J, Hanewinckel, R, Ikram, MA, van Doorn, PA. Prevalence and risk factor profiles for chronic axonal polyneuropathy in the general population. Neurology 2022:10.1212/WNL.0000000000201168. doi: 10.1212/WNL.0000000000201168. Epub ahead of print. PMID: 36008153.Google Scholar

Vallat, JM, Duchesne, M, Corcia, P, et al. The wide spectrum of pathophysiologic mechanisms of paraproteinemic neuropathy. Neurology 2021;96(5):214–225. doi: 10.1212/WNL.0000000000011324. Epub 2020 Dec 4. PMID: 33277411.CrossRefGoogle ScholarPubMed

Bou Zerdan, M, George, TI, Bunting, ST, Chaulagain, CP. Recent advances in the treatment and supportive care of POEMS syndrome. J Clin Med 2022;11(23):7011. doi: 10.3390/jcm11237011. PMID: 36498588; PMCID: PMC9741379.CrossRefGoogle ScholarPubMed

Dispenzieri, A. POEMS syndrome: 2019 update on diagnosis, risk-stratification, and management. Am J Hematol 2019;94(7):812–827. doi: 10.1002/ajh.25495. Epub 2019 May 23. PMID: 31012139.CrossRefGoogle ScholarPubMed

D’Sa, S, Khwaja, J, Keddie, S, et al. Comprehensive diagnosis and management of POEMS syndrome. Hemasphere 2022;6(11):e796. doi: 10.1097/HS9.0000000000000796. PMID: 36340912; PMCID: PMC9624442.CrossRefGoogle ScholarPubMed

Khouri, J, Nakashima, M, Wong, S. Update on the diagnosis and treatment of POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome: a review. JAMA Oncol 2021;7(9):1383–1391. doi: 10.1001/jamaoncol.2021.0586. PMID: 34081097.CrossRefGoogle ScholarPubMed

Kim, YR. Update on the POEMS syndrome. Blood Res 2022;57(S1):27–31. doi: 10.5045/br.2022.2022001. PMID: 35483922; PMCID: PMC9057663.CrossRefGoogle ScholarPubMed

Collins, MP, Dyck, PJB, Hadden, RDM. Update on classification, epidemiology, clinical phenotype and imaging of the nonsystemic vasculitic neuropathies. Curr Opin Neurol 2019;32(5):684–695. doi: 10.1097/WCO.0000000000000727. PMID: 31313704.CrossRefGoogle ScholarPubMed

Gwathmey, KG, Tracy, JA, Dyck, PJB. Peripheral nerve vasculitis: classification and disease associations. Neurol Clin 2019;37(2):303–333. doi: 10.1016/j.ncl.2019.01.013. Epub 2019 Mar 18. PMID: 30952411.CrossRefGoogle ScholarPubMed

Koike, H, Nishi, R, Ohyama, K, et al. ANCA-associated vasculitic neuropathies: a review. Neurol Ther 2022;11(1):21–38. doi: 10.1007/s40120-021-00315-7. Epub 2022 Jan 19. PMID: 35044596; PMCID: PMC8857368.CrossRefGoogle ScholarPubMed

Chan, ACY, Kumar, S, Tan, G, et al. Expanding the genetic causes of small-fiber neuropathy: SCN genes and beyond. Muscle Nerve 2023;67(4):259–271. doi: 10.1002/mus.27752. Epub 2022 Nov 30. PMID: 36448457.CrossRefGoogle ScholarPubMed

Devigili, G, Cazzato, D, Lauria, G. Clinical diagnosis and management of small fiber neuropathy: an update on best practice. Expert Rev Neurother 2020;20(9):967–980. doi: 10.1080/14737175.2020.1794825. Epub 2020 Jul 23. PMID: 32654574.CrossRefGoogle ScholarPubMed

Geerts, M, de Greef, BTA, Sopacua, M, et al. Intravenous immunoglobulin therapy in patients with painful idiopathic small fiber neuropathy. Neurology 2021;96(20):e2534–e2545. doi: 10.1212/WNL.0000000000011919. Epub 2021 Mar 25. PMID: 33766992; PMCID: PMC8205474.CrossRefGoogle ScholarPubMed

Hoeijmakers, JGJ, Merkies, ISJ, Faber, CG. Small fiber neuropathies: expanding their etiologies. Curr Opin Neurol 2022;35(5):545–552. doi: 10.1097/WCO.0000000000001103. Epub 2022 Aug 11. PMID: 35950732.Google ScholarPubMed

Sopacua, M, Hoeijmakers, JGJ, Merkies, ISJ, et al. Small-fiber neuropathy: expanding the clinical pain universe. J Peripher Nerv Syst 2019;24(1):19–33. doi: 10.1111/jns.12298. Epub 2019 Jan 8. PMID: 30569495.CrossRefGoogle ScholarPubMed

Terkelsen, AJ, Karlsson, P, Lauria, G, et al. The diagnostic challenge of small fibre neuropathy: clinical presentations, evaluations, and causes. Lancet Neurol 2017;16(11):934–944. doi: 10.1016/S1474-4422(17)30329-0. Erratum in: Lancet Neurol. 2017 Dec;16(12):954. PMID: 29029847.CrossRefGoogle ScholarPubMed

Amato, AA, Ropper, AH. Sensory ganglionopathy. i 2020;383(17):1657–1662. doi: 10.1056/NEJMra2023935. PMID: 33085862.Google ScholarPubMed

Antoine, JC. Sensory neuronopathies, diagnostic criteria and causes. Curr Opin Neurol 2022;35(5):553–561. doi: 10.1097/WCO.0000000000001105. Epub 2022 Aug 11. PMID: 35950727.Google ScholarPubMed

Camdessanché, JP, Jousserand, G, Ferraud, K, et al. The pattern and diagnostic criteria of sensory neuronopathy: a case-control study. Brain 2009;132:1723–1733. doi: 10.1093/brain/awp136. Epub 2009 Jun 8. PMID: 19506068; PMCID: PMC2702838.CrossRefGoogle ScholarPubMed

Fargeot, G, Echaniz-Laguna, A. Sensory neuronopathies: new genes, new antibodies and new concepts. J Neurol Neurosurg Psychiatry 2021;jnnp-2020-325536. doi: 10.1136/jnnp-2020-325536. Epub ahead of print. PMID: 33563795.CrossRefGoogle Scholar

Graus, F, Vogrig, A, Muñiz-Castrillo, S, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm 2021;8(4):e1014. doi: 10.1212/NXI.0000000000001014. PMID: 34006622; PMCID: PMC8237398.CrossRefGoogle ScholarPubMed

Titulaer, MJ, Soffietti, R, Dalmau, J, et al.; European Federation of Neurological Societies.Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011;18(1):19–e3. doi: 10.1111/j.1468-1331.2010.03220.x. Epub 2010 Sep 29. PMID: 20880069; PMCID: PMC3086523.CrossRefGoogle ScholarPubMed

Collins, MP, Hadden, RD. The nonsystemic vasculitic neuropathies. Nat Rev Neurol 2017;13(5):302–316. doi: 10.1038/nrneurol.2017.42. PMID: 28447661.Google ScholarPubMed

Herraets, IJT, Goedee, HS, Telleman, JA, et al. High-resolution ultrasound in patients with Wartenberg’s migrant sensory neuritis, a case-control study. Clin Neurophysiol 2018;129(1):232–237. doi: 10.1016/j.clinph.2017.10.040. Epub 2017 Nov 21. PMID: 29202391.CrossRefGoogle ScholarPubMed

Stork, AC, van der Meulen, MF, van der Pol, WL, et al. Wartenberg’s migrant sensory neuritis: a prospective follow-up study. J Neurol 2010;257(8):1344–1348. doi: 10.1007/s00415-010-5530-7. Epub 2010 Mar 31. PMID: 20354714; PMCID: PMC2910306.CrossRefGoogle ScholarPubMed

Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – first revision. J Peripher Nerv Syst 2010;15(4):295–301. doi: 10.1111/j.1529-8027.2010.00290.x. PMID: 21199100.CrossRefGoogle Scholar

Keddie, S, Eftimov, F, van den Berg, LH, et al. Immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev 2022;1(1):CD004429. doi: 10.1002/14651858.CD004429.pub3. PMID: 35015296; PMCID: PMC8751207.Google ScholarPubMed

Oudeman, J, Eftimov, F, Strijkers, GJ, et al. Diagnostic accuracy of MRI and ultrasound in chronic immune-mediated neuropathies. Neurology 2020;94(1):e62–e74. doi: 10.1212/WNL.0000000000008697. Epub 2019 Dec 11. PMID: 31827006.CrossRefGoogle ScholarPubMed

Telleman, JA, Herraets, IJ, Goedee, HS, van Asseldonk, JT, Visser, LH. Ultrasound scanning in the diagnosis of peripheral neuropathies. Pract Neurol 2021;21(3):186–195. doi: 10.1136/practneurol-2020-002645. Epub 2021 Feb 4. PMID: 33541914.CrossRefGoogle ScholarPubMed

Vlam, L, van der Pol, WL, Cats, EA, et al. Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol 2011;8(1):48–58. doi: 10.1038/nrneurol.2011.175. PMID: 22105211.CrossRefGoogle ScholarPubMed

Yeh, WZ, Dyck, PJ, van den Berg, LH, Kiernan, MC, Taylor, BV. Multifocal motor neuropathy: controversies and priorities. J Neurol Neurosurg Psychiatry 2020;91(2):140–148. doi: 10.1136/jnnp-2019-321532. Epub 2019 Sep 11. PMID: 31511307.CrossRefGoogle ScholarPubMed

De Wel, B, Claeys, KG. Neuromuscular hyperexcitability syndromes. Curr Opin Neurol 2021;34(5):714–720. doi: 10.1097/WCO.0000000000000963. PMID: 34914668.CrossRefGoogle ScholarPubMed

Sawlani, K, Katirji, B. Peripheral nerve hyperexcitability syndromes. Continuum (Minneap Minn) 2017;23(5, Peripheral Nerve and Motor Neuron Disorders):1437–1450. doi: 10.1212/CON.0000000000000520. PMID: 28968370.Google ScholarPubMed

IJspeert, J, Janssen, RMJ, van Alfen, N. Neuralgic amyotrophy. Curr Opin Neurol 2021;34(5):605–612. doi: 10.1097/WCO.0000000000000968. PMID: 34054111.CrossRefGoogle ScholarPubMed

Janssen, RMJ, Lustenhouwer, R, Cup, EHC, et al. Effectiveness of an outpatient rehabilitation programme in patients with neuralgic amyotrophy and scapular dyskinesia: a randomised controlled trial. J Neurol Neurosurg Psychiatry 2023;94(6):474–481. doi: 10.1136/jnnp-2022-330296. Epub 2023 Jan 25. PMID: 36697215.CrossRefGoogle ScholarPubMed

Klein, CJ, Barbara, DW, Sprung, J, Dyck, PJ, Weingarten, TN. Surgical and postpartum hereditary brachial plexus attacks and prophylactic immunotherapy. Muscle Nerve 2013;47(1):23–27. doi: 10.1002/mus.23462. Epub 2012 Oct 5. PMID: 23042485; PMCID: PMC3528817.CrossRefGoogle ScholarPubMed

van Eijk, JJJ, Dalton, HR, Ripellino, P, et al. Clinical phenotype and outcome of hepatitis E virus-associated neuralgic amyotrophy. Neurology 2017;89(9):909–917. doi: 10.1212/WNL.0000000000004297. Epub 2017 Aug 2. PMID: 28768846.CrossRefGoogle ScholarPubMed

Feldman, EL, Callaghan, BC, Pop-Busui, R, et al. Diabetic neuropathy. Nat Rev Dis Primers 2019;5(1):41. doi: 10.1038/s41572-019-0092-1. PMID: 31197153.CrossRefGoogle ScholarPubMed

Izenberg, A, Perkins, BA, Bril, V. Diabetic neuropathies. Semin Neurol 2015;35(4):424–430. doi: 10.1055/s-0035-1558972. Epub 2015 Oct 6. PMID: 26502765.Google ScholarPubMed

Ng, PS, Dyck, PJ, Laughlin, RS, et al. Lumbosacral radiculoplexus neuropathy: incidence and the association with diabetes mellitus. Neurology 2019;92(11):e1188–e1194. doi: 10.1212/WNL.0000000000007020. Epub 2019 Feb 13. PMID: 30760636; PMCID: PMC6511105.CrossRefGoogle ScholarPubMed

Hamel, J, Logigian, EL. Acute nutritional axonal neuropathy. Muscle Nerve 2018;57(1):33–39. doi: 10.1002/mus.25702. Epub 2017 Jun 19. PMID: 28556429.CrossRefGoogle ScholarPubMed

Hanewinckel, R, van Oijen, M, Ikram, MA, van Doorn, PA. The epidemiology and risk factors of chronic polyneuropathy. Eur J Epidemiol 2016;31(1):5–20. doi: 10.1007/s10654-015-0094-6. Epub 2015 Dec 23. PMID: 26700499; PMCID: PMC4756033.CrossRefGoogle ScholarPubMed

Julian, T, Glascow, N, Syeed, R, Zis, P. Alcohol-related peripheral neuropathy: a systematic review and meta-analysis. J Neurol 2019;266(12):2907–2919. doi: 10.1007/s00415-018-9123-1. Epub 2018 Nov 22. PMID: 30467601; PMCID: PMC6851213.CrossRefGoogle ScholarPubMed

Hanewinckel, R, van Oijen, M, Ikram, MA, van Doorn, PA. The epidemiology and risk factors of chronic polyneuropathy. Eur J Epidemiol 2016 Jan;31(1):5–20. doi: 10.1007/s10654-015-0094-6. Epub 2015 Dec 23. PMID: 26700499; PMCID: PMC4756033.CrossRefGoogle ScholarPubMed

Hanewinckel, R, van Oijen, M, Taams, NE, et al. Diagnostic value of symptoms in chronic polyneuropathy: the Erasmus Polyneuropathy Symptom Score. J Peripher Nerv Syst 2019;24(3):235–241. doi: 10.1111/jns.12328. Epub 2019 Jul 9. PMID: 31172622.CrossRefGoogle ScholarPubMed

Taams, NE, Drenthen, J, Hanewinckel, R, Ikram, MA, van Doorn, PA. Prevalence and risk factor profiles for chronic axonal polyneuropathy in the general population. Neurology 2022:10.1212/WNL.0000000000201168. doi: 10.1212/WNL.0000000000201168. Epub ahead of print. PMID: 36008153.Google Scholar

Visser, NA, Notermans, NC, Linssen, RS, van den Berg LH, , Vrancken, AF. Incidence of polyneuropathy in Utrecht, the Netherlands. Neurology 2015;84(3):259–264. doi: 10.1212/WNL.0000000000001160. Epub 2014 Dec 12. PMID: 25503982.CrossRefGoogle ScholarPubMed

Vrancken, AF, Franssen, H, Wokke, JH, Teunissen, LL, Notermans, NC. Chronic idiopathic axonal polyneuropathy and successful aging of the peripheral nervous system in elderly people. Arch Neurol 2002;59(4):533–340. doi: 10.1001/archneur.59.4.533. PMID: 11939887.CrossRefGoogle ScholarPubMed

Kress, JP, Hall, JB. ICU-acquired weakness and recovery from critical illness. N Engl J Med 2014;370(17):1626–1635. doi: 10.1056/NEJMra1209390. PMID: 24758618.CrossRefGoogle ScholarPubMed

Vanhorebeek, I, Latronico, N, Van den Berghe, G. ICU-acquired weakness. Intensive Care Med 2020;46(4):637–653. doi: 10.1007/s00134-020-05944-4. Epub 2020 Feb 19. PMID: 32076765; PMCID: PMC7224132.CrossRefGoogle ScholarPubMed

Orr, CF, Ahlskog, JE. Frequency, characteristics, and risk factors for amiodarone neurotoxicity. Arch Neurol 2009;66(7):865–869. doi: 10.1001/archneurol.2009.96. PMID: 19597088.CrossRefGoogle ScholarPubMed

Peters, J, Staff, NP. Update on toxic neuropathies. Curr Treat Options Neurol 2022;24(5):203–216. doi: 10.1007/s11940-022-00716-5. Epub 2022 Apr 6. PMID: 36186669; PMCID: PMC9518699.CrossRefGoogle ScholarPubMed

Smyth, D, Kramarz, C, Carr, AS, Rossor, AM, Lunn, MP. Toxic neuropathies: a practical approach. Pract Neurol 2023;23(2):120–130. doi: 10.1136/pn-2022-003444. Epub 2023 Jan 25. PMID: 36697225.CrossRefGoogle ScholarPubMed

Stähli, BE, Schwab, S. Amiodarone-induced skin hyperpigmentation. QJM 2011;104(8):723–724. doi: 10.1093/qjmed/hcq131. Epub 2010 Jul 30. PMID: 20675394.CrossRefGoogle ScholarPubMed

Vassallo, P, Trohman, RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 2007;298(11):1312–1322. doi: 10.1001/jama.298.11.1312. PMID: 17878423.CrossRefGoogle ScholarPubMed

Dutta, A, Hunter, JV, Vallejo, JG. Bannwarth syndrome: a rare manifestation of pediatric Lyme neuroborreliosis. Pediatr Infect Dis J 2021;40(11):e442–e444. doi: 10.1097/INF.0000000000003245. PMID: 34636801.CrossRefGoogle ScholarPubMed

Garcia-Monco, JC, Benach, JL. Lyme neuroborreliosis: clinical outcomes, controversy, pathogenesis, and polymicrobial infections. Ann Neurol 2019;85(1):21–31. doi: 10.1002/ana.25389. PMID: 30536421; PMCID: PMC7025284.Google ScholarPubMed

Kortela, E, Kanerva, MJ, Puustinen, J, et al. Oral doxycycline compared to intravenous ceftriaxone in the treatment of Lyme neuroborreliosis: a multicenter, equivalence, randomized, open-label trial. Clin Infect Dis 2021;72(8):1323–1331. doi: 10.1093/cid/ciaa217. PMID: 32133487.CrossRefGoogle ScholarPubMed

Nordberg, CL, Bodilsen, J, Knudtzen, FC, et al.; DASGIB study group.Lyme neuroborreliosis in adults: a nationwide prospective cohort study. Ticks Tick Borne Dis 2020;11(4):101411. doi: 10.1016/j.ttbdis.2020.101411. Epub 2020 Feb 24. PMID: 32178995.CrossRefGoogle ScholarPubMed

van Samkar, A, Bruinsma, RA, Vermeeren, YM, et al. Clinical characteristics of Lyme neuroborreliosis in Dutch children and adults. Eur J Pediatr 2023;182(3):1183–1189. doi: 10.1007/s00431-022-04749-5. Epub 2023 Jan 6. PMID: 36607413.CrossRefGoogle ScholarPubMed

Giesel, LM, Hökerberg, YHM, Pitta, IJR, et al. Clinical prediction rules for the diagnosis of neuritis in leprosy. BMC Infect Dis 2021;21(1):858. doi: 10.1186/s12879-021-06545-2. PMID: 34425777; PMCID: PMC8381570.CrossRefGoogle ScholarPubMed

Tomaselli, PJ, Dos Santos, DF, Dos Santos, ACJ, et al. Primary neural leprosy: clinical, neurophysiological and pathological presentation and progression. Brain 2022;145(4):1499–1506. doi: 10.1093/brain/awab396. PMID: 34664630.CrossRefGoogle ScholarPubMed

World Health Organization. Towards Zero Leprosy: Global Leprosy (Hansen’s Disease) Strategy 2021–2030. (who.int). Jan 27, 2023. ISBN: 978 92 9022 850 9Google Scholar

Bird, TD. Charcot-Marie-Tooth hereditary neuropathy overview. 1998 Sep 28 [updated 2023 Feb 23]. In Adam, MP, Mirzaa, GM, Pagon, RA, et al., editors. GeneReviews® [Internet]. Seattle, WA: University of Washington; 1993–2023. PMID: 20301532.Google Scholar

Corrado, B, Ciardi, G, Bargigli, C. Rehabilitation management of the Charcot-Marie-Tooth syndrome: a systematic review of the literature. Medicine (Baltimore) 2016;95(17):e3278. doi: 10.1097/MD.0000000000003278. PMID: 27124017; PMCID: PMC4998680.CrossRefGoogle ScholarPubMed

Klein, CJ. Charcot-Marie-Tooth disease and other hereditary neuropathies. Continuum (Minneap Minn) 2020;26(5):1224–1256. doi: 10.1212/CON.0000000000000927. Erratum in: Continuum (Minneap Minn). 2021 Feb 1;27(1):289. PMID: 33003000.Google ScholarPubMed

Kramarz, C, Rossor, AM. Neurological update: hereditary neuropathies. J Neurol 2022;269(9):5187–5191. doi: 10.1007/s00415-022-11164-1. Epub 2022 May 21. PMID: 35596796; PMCID: PMC9363318.Google ScholarPubMed

Nagappa, M, Sharma, S, Taly, AB. Charcot-Marie-Tooth disease. 2022 Aug 22. In StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2023 Jan–. PMID: 32965834.Google Scholar

Zambon, AA, Pini, V, Bosco, L, et al. Early onset hereditary neuronopathies: an update on non-5q motor neuron diseases. Brain 2023;146(3):806–822. doi: 10.1093/brain/awac452. PMID: 36445400; PMCID: PMC9976982.CrossRefGoogle ScholarPubMed

Abati, E, Manini, A, Velardo, D, et al. Clinical and genetic features of a cohort of patients with MFN2-related neuropathy. Sci Rep 2022;12(1):6181. doi: 10.1038/s41598-022-10220-0. PMID: 35418194; PMCID: PMC9008012.CrossRefGoogle ScholarPubMed

Cortese, A, Zhu Y, Rebelo AP et al. Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes. Nat Genet. 2020 May;52(5):473-481. doi: 10.1038/s41588-020-0615–4. Epub 2020 May 4.CrossRefGoogle Scholar

Farrugia, PR, Bednar, D, Oitment, C. Charcot arthropathy of the spine. J Am Acad Orthop Surg 2022;30(21):e1358–e1365. doi: 10.5435/JAAOS-D-22-00212. Epub 2022 Aug 25. PMID: 36007201.Google ScholarPubMed

Fridman, V, Suriyanarayanan, S, Novak, P, et al. Randomized trial of L-serine in patients with hereditary sensory and autonomic neuropathy type 1. Neurology 2019;92(4):e359–e370. doi: 10.1212/WNL.0000000000006811. Epub 2019 Jan 9. PMID: 30626650; PMCID: PMC6345118.CrossRefGoogle ScholarPubMed

González-Duarte, A, Cotrina-Vidal, M, Kaufmann, H, Norcliffe-Kaufmann, L. Familial dysautonomia. Clin Auton Res 2023;33(3):269–280. doi: 10.1007/s10286-023-00941-1. Epub 2023 May 19. PMID: 37204536.CrossRefGoogle ScholarPubMed

Schwartzlow, C, Kazamel, M. Hereditary sensory and autonomic neuropathies: adding more to the classification. Curr Neurol Neurosci Rep 2019;19(8):52. doi: 10.1007/s11910-019-0974-3. PMID: 31222456.CrossRefGoogle ScholarPubMed

Sethi, PK, Sethi, NK. Charcot joint. Ann Neurol 2022;91(3):436–437. doi: 10.1002/ana.26310. Epub 2022 Feb 10. PMID: 35084055CrossRefGoogle ScholarPubMed

Aimo, A, Castiglione, V, Rapezzi, C, et al. RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nat Rev Cardiol 2022;19(10):655–667. doi: 10.1038/s41569-022-00683-z. Epub 2022 Mar 23. PMID: 35322226.CrossRefGoogle ScholarPubMed

Carroll, A, Dyck, PJ, de Carvalho, M, et al. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. J Neurol Neurosurg Psychiatry 2022;93(6):668–678. doi: 10.1136/jnnp-2021-327909. Epub 2022 Mar 7. PMID: 35256455; PMCID: PMC9148983.CrossRefGoogle ScholarPubMed

Gillmore, JD, Gane, E, Taubel, J, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med 2021;385(6):493–502. doi: 10.1056/NEJMoa2107454. Epub 2021 Jun 26. PMID: 34215024.CrossRefGoogle ScholarPubMed

Kaku, M, Berk, JL. Neuropathy associated with systemic amyloidosis. Semin Neurol 2019;39(5):578–588. doi: 10.1055/s-0039-1688994. Epub 2019 Oct 22. PMID: 31639841.Google ScholarPubMed

Magrinelli, F, Fabrizi, GM, Santoro, L, et al. Pharmacological treatment for familial amyloid polyneuropathy. Cochrane Database Syst Rev 2020;4(4):CD012395. doi: 10.1002/14651858.CD012395.pub2. PMID: 32311072; PMCID: PMC7170468.Google ScholarPubMed

Plante-Bordeneuve, V. Transthyretin familial amyloid polyneuropathy: an update. J Neurol 2018;265(4):976–983. doi: 10.1007/s00415-017-8708-4. Epub 2017 Dec 16. PMID: 29249054.CrossRefGoogle ScholarPubMed

Wisniowski, B, Wechalekar, A. Confirming the diagnosis of amyloidosis. Acta Haematol 2020;143(4):312–321. doi: 10.1159/000508022. Epub 2020 Jun 16. PMID: 32544917.CrossRefGoogle ScholarPubMed